Actively Recruiting
A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer
Led by Zhejiang University · Updated on 2024-12-27
30
Participants Needed
1
Research Sites
107 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-center, single-arm, open-label, dose-escalation clinical study to evaluate the safety and anti-tumor efficacy of second-line systemic chemotherapy sequential NKG2D CAR-NK cell therapy for pancreatic cancer
CONDITIONS
Official Title
A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years old, both male and female
- Histologically or cytologically confirmed pancreatic ductal adenocarcinoma or IPMN carcinosis with failure of at least first-line systemic therapy
- ECOG performance status score between 0 and 2
- Life expectancy of at least 3 months at screening
- At least one stable target lesion evaluable by RECIST 1.1 criteria
- Adequate organ and bone marrow function with stable laboratory results, no ongoing supportive care except allowed bile duct interventions
- Recovery of prior therapy toxicities to Grade 0-1 or acceptable levels
- Not pregnant and willing to use effective contraception if of childbearing potential, from consent signing until 6 months after last infusion
- Signed written informed consent
- Voluntary and able to comply with treatment, tests, follow-up, and study requirements
You will not qualify if you...
- Pregnant or breastfeeding females
- Positive serology for HIV, Treponema pallidum, or active HCV infection (HCV antibody positive but RNA negative, stable syphilis, and inactive patients allowed)
- Any active infection requiring treatment, including tuberculosis, HBV, EBV, CMV, novel coronavirus, or other bacterial, viral, or fungal infections
- History of other malignancies within 5 years except basal cell skin cancer or cervical carcinoma in situ
- Any other health condition judged by the investigator to prevent study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the first affiliated hospital of Zhejiang University，school of medicine
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
Research Team
Q
Qi Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here